Dupont Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Dupont Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-72,200	Closed	-$8.35M	–	223
2023 Q3	$8.35M	Hold	72,200	–	–	0.73%	52
2023 Q2	$7.43M	Hold	72,200	–	–	0.37%	54
2023 Q1	$7.88M	Buy	72,200 +32,350	+81%	+$3.58M	0.38%	52
2022 Q4	$4.53M	Buy	39,850 +26,265	+193%	+$2.18M	0.21%	65
2022 Q3	$841K	Sell	13,585 -8,037	-37%	-$562K	0.05%	461
2022 Q2	$1.73M	Buy	21,622 +6,239	+41%	+$591K	0.08%	252
2022 Q1	$1.62M	Buy	15,383 +6,903	+81%	+$673K	0.07%	298
2021 Q4	$914K	Sell	8,480 -1,495	-15%	-$163K	0.03%	591
2021 Q3	$1.09M	Buy	9,975 +8,066	+423%	+$837K	0.03%	504
2021 Q2	$179K	Buy	+1,909	New	+$176K	﹤0.01%	1325
2019 Q3	–	Sell	-23,134	Closed	-$557K	–	1328
2019 Q2	$557K	Buy	+23,134	New	+$587K	0.01%	738

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Dupont Capital Management's HZNP Position: Q4 2023 in Review

Dupont Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 72,200 shares — an estimated $8.35M sold.

Dupont Capital Management first reported a position in HZNP in Q2 2019 and held it in 11 quarters. The position peaked at $8.35M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Dupont Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Dupont Capital Management sold 72,200 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $8.35M.
Dupont Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2019 and held it in 11 quarters.
Dupont Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $8.35M in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Dupont Capital Management's 13F filing for Q4 2023, filed 23 Jan 2024.